Study Evaluating Enbrel in Patients With Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT00245934
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to investigate the incidence of adverse events for patients with rheumatoid arthritis treated with Enbrel under usual care settings. In addition, differences in injection site reactions based on whether health care professionals or patients administer Enbrel will be assessed and evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
- Proven diagnosis of rheumatoid arthritis
Exclusion Criteria
-
Contraindications according to Summary of Product Characteristic (SmPC)of Enbrel® the following points will prevent or restrict participation:
- Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®
- Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localized infections
- Patients with sepsis or risk of sepsis should not be treated
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Enbrel in rheumatoid arthritis pathogenesis?
How does Enbrel compare to other TNF inhibitors in managing RA adverse events?
Which biomarkers correlate with Enbrel response in rheumatoid arthritis patients?
What are the most common injection site reactions in self-administered vs. professional Enbrel use?
How does Enbrel's efficacy in RA compare to non-biologic DMARDs like methotrexate?